Dermatology

Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy.




Icon for Elsevier Science Icon for PubMed Central Related Articles

Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy.

J Am Acad Dermatol. 2020 Oct;83(4):1215-1218

Authors: Holcomb ZE, Santillan MR, Morss-Walton PC, Salian P, Her MJ, Giannotti NM, Kimball AB, Porter ML

PMID: 32622141 [PubMed - indexed for MEDLINE]

Source link







Related posts

Vitiligo, From Physiopathology to Emerging Treatments: A Review.

Newsemia

The Apex Approach to Maskne (and all acne!)

Newsemia

Case 26-2018: A 48-Year-Old Man with Fever, Chills, Myalgias, and Rash.

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy